{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:21:07Z","timestamp":1789734067366,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijgc.2025.101673","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T21:49:15Z","timestamp":1738273755000},"page":"101673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Controversies in the management of serous borderline tumors and low-grade serous ovarian cancer"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9725-9550","authenticated-orcid":false,"given":"Narthana","family":"Ilenkovan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3117-3257","authenticated-orcid":false,"given":"Neil","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9869-591X","authenticated-orcid":false,"given":"Patricia","family":"Roxburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-7221","authenticated-orcid":false,"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10177","key":"10.1016\/j.ijgc.2025.101673_bib1","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101673_bib2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","article-title":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","volume":"33","author":"Grisham","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.101673_bib3","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/IGC.0000000000000257","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas","volume":"24","author":"Gourley","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101673_bib4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101673_bib5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.pas.0000164030.82810.db","article-title":"Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (\u22655-year) follow-up","volume":"29","author":"Longacre","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib6","first-page":"3","article-title":"Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential","volume":"99","author":"Crispens","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"suppl 1","key":"10.1016\/j.ijgc.2025.101673_bib7","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/annonc\/mdw089","article-title":"The molecular pathology of ovarian serous borderline tumors","volume":"27","author":"Malpica","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ygyno.2007.01.030","article-title":"Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma","volume":"105","author":"Shvartsman","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101673_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1074-3804(00)80043-2","article-title":"Endosalpingiosis in laparoscopy","volume":"7","author":"Hesseling","year":"2000","journal-title":"J Am Assoc Gynecol Laparosc"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0015-0282(16)57780-2","article-title":"Endosalpingiosis found at laparoscopy for chronic pelvic pain","volume":"64","author":"Keltz","year":"1995","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101673_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/path.5353","article-title":"Oncogenic BRAF and KRAS mutations in endosalpingiosis","volume":"250","author":"Chui","year":"2020","journal-title":"J Pathol"},{"issue":"10324","key":"10.1016\/j.ijgc.2025.101673_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.ijgc.2025.101673_bib13","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, Fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101673_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2023.04.011","article-title":"Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome","volume":"174","author":"Thomson","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"64","key":"10.1016\/j.ijgc.2025.101673_bib15","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.18632\/oncotarget.27326","article-title":"BRAFV600E -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma","volume":"10","author":"Chui","year":"2019","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib16","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101673_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.47343","article-title":"Outcomes from opportunistic salpingectomy for ovarian cancer prevention","volume":"5","author":"Hanley","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101673_bib19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ygyno.2022.09.022","article-title":"Genomic profiling in low grade serous ovarian cancer: identification of novel markers for disease diagnosis and therapy","volume":"167","author":"ElNaggar","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101673_bib20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jmoldx.2023.12.004","article-title":"Somatic genomic and transcriptomic characterization of primary ovarian serous borderline tumors and low-grade serous carcinomas","volume":"26","author":"Stru\u017einsk\u00e1","year":"2024","journal-title":"J Mol Diagn"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101673_bib60","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/path.4252","article-title":"KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma","volume":"231","author":"Tsang","year":"2013","journal-title":"J Pathol"},{"issue":"34","key":"10.1016\/j.ijgc.2025.101673_bib64","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1200\/JCO.2015.62.4726","article-title":"Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer","volume":"33","author":"Grisham","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101673_bib61","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s41416-022-01897-1","article-title":"Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)","volume":"127","author":"Musacchio","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib62","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12967-022-03820-x","article-title":"Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors","volume":"20","author":"Wong","year":"2022","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib65","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.1038\/s41598-023-34627-5","article-title":"Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma","volume":"13","author":"Hollis","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101673_bib63","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jmoldx.2023.12.004","article-title":"Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas","volume":"26","author":"Stru\u017einsk\u00e1","year":"2024","journal-title":"J Mol Diagn"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101673_bib21","first-page":"161","article-title":"Histologic subtypes of ovarian carcinoma: an overview","volume":"27","author":"Soslow","year":"2008","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib22","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/PAS.0b013e31823732a9","article-title":"Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon","volume":"36","author":"Boyd","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101673_bib23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/PAS.0b013e31802cbbe9","article-title":"The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis","volume":"31","author":"Dehari","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101673_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/PGP.0b013e31824ae6f2","article-title":"Low-grade serous neoplasms of the ovary with transformation to high-grade carcinomas: a report of 3 cases","volume":"31","author":"Garg","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ijgc.2025.101673_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/20363613231172260","article-title":"Ovarian serous borderline tumor with mural nodules of anaplastic carcinoma and omental involvement: a case report","volume":"15","author":"Hernandez Acevedo","year":"2023","journal-title":"Rare Tumors"},{"key":"10.1016\/j.ijgc.2025.101673_bib26","article-title":"A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF\/MEK inhibitor combination","volume":"54","author":"Singh","year":"2024","journal-title":"Gynecol Oncol Rep"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/PGP.0000000000000885","article-title":"Borderline with bad behavior: an unusual low-grade serous carcinoma with dedifferentiation from a serous borderline tumor","volume":"42","author":"Strickland","year":"2023","journal-title":"Int J Gynecol Pathol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101673_bib28","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/PAS.0000000000002294","article-title":"High-grade anaplastic transformation of ovarian serous borderline tumor: a distinctive morphology with abundant dense eosinophilic cytoplasm and dismal prognosis","volume":"48","author":"Zhang","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/PAS.0000000000001419","article-title":"Clinicopathologic, immunohistochemical, and molecular characteristics of ovarian serous carcinoma with mixed morphologic features of high-grade and low-grade serous carcinoma","volume":"44","author":"Zarei","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/PGP.0000000000000207","article-title":"Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in the cancer genome atlas ovarian study","volume":"35","author":"Vang","year":"2016","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100629","article-title":"Early genetic divergence of high-grade carcinomas originating from low-grade serous ovarian neoplasms","volume":"38","author":"Chui","year":"2025","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.101673_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejogrb.2024.01.003","article-title":"Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma","volume":"294","author":"Petiot","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13048-021-00925-7","article-title":"Uterine involvement in epithelial ovarian cancer and its risk factors","volume":"14","author":"Zamani","year":"2021","journal-title":"J Ovarian Res"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/ijgc-2020-001804","article-title":"Uterus transplantation for fertility preservation in patients with gynecologic cancer","volume":"31","author":"Dahm-K\u00e4hler","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101673_bib36","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_431818","article-title":"Innovations in rare gynecologic cancer: melanoma, neuroendocrine, and low-grade serous ovarian","volume":"44","author":"Au-Yeung","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2020.06.498","article-title":"The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance","volume":"158","author":"Cobb","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.101673_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.970918","article-title":"Advanced low grade serous ovarian cancer: a retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers","volume":"12","author":"Di Lorenzo","year":"2022","journal-title":"Front Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101673_bib40","article-title":"A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma","volume":"40","author":"Cobb","year":"2022","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2014.11.005","article-title":"The role\u00a0of\u00a0secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer","volume":"136","author":"Crane","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ygyno.2021.10.080","article-title":"Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: a systematic review and meta-analysis","volume":"164","author":"Goldberg","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101673_bib43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/ijgc-2023-004854","article-title":"Low-grade versus high-grade serous ovarian cancer: comparison of surgical outcomes after secondary cytoreductive surgery","volume":"34","author":"Cappuccio","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2025.101673_bib45","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.34753","article-title":"Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: readdressing the roles of platinum and cytotoxic therapies","volume":"129","author":"Manning-Geist","year":"2023","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101673_bib46","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib47","first-page":"36","article-title":"Low-grade serous carcinoma (LGSC): a Canadian multicenter review of practice patterns and patient outcomes","volume":"157","author":"Scott","year":"2020","journal-title":"Gynecol\u00a0Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101673_bib48","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1136\/ijgc-2023-004745","article-title":"Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery","volume":"33","author":"Nasioudis","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"26","key":"10.1016\/j.ijgc.2025.101673_bib50","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2017.01.027","article-title":"Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience","volume":"145","author":"Dalton","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101673_bib52","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IGC.0000000000000190","article-title":"Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer","volume":"24","author":"Grisham","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101673_bib53","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/IGC.0000000000000742","article-title":"Activity of bevacizumab in patients with low-grade serous ovarian carcinoma","volume":"26","author":"Rose","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 1","key":"10.1016\/j.ijgc.2025.101673_bib54","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ygyno.2023.06.466","article-title":"GOG 3026 a phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: a GOG foundation study (001)","volume":"176","author":"Slomovitz","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101673_bib55","article-title":"Initial efficacy and safety results from ENGOT-ov60\/GOG-3052\/RAMP 201: a phase 2 study of avutometinib (VS-6766)\u00a0\u00b1 defactinib in recurrent low-grade serous ovarian cancer (LGSOC)","volume":"41","author":"Banerjee","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101673_bib56","first-page":"2235","article-title":"Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines","volume":"6","author":"Fern\u00e1ndez","year":"2016","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ijgc.2025.101673_bib57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2024.03.029","article-title":"High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma","volume":"186","author":"Hollis","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib58","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41597-024-03869-x","article-title":"High-throughput drug screening identifies novel therapeutics for Low Grade serous Ovarian Carcinoma","volume":"11","author":"Pishas","year":"2024","journal-title":"Sci Data"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101673_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77666-y","article-title":"Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations","volume":"10","author":"Kun","year":"2020","journal-title":"Sci Rep"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25001987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:55:15Z","timestamp":1748321715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25001987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1048891X25001987"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101673","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in the management of serous borderline tumors and low-grade serous ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101673","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"101673"}}